Bolduc Jean Philippe, Oliva Vincent L, Therasse Eric, Giroux Marie-France, Bouchard Louis, Perreault Pierre, Cliché Andrée, Soulez Gilles
Department of Radiology, CHUM-Notre-Dame Hospital, 1560 Sherbrooke East, Montreal, Quebec, Canada.
AJR Am J Roentgenol. 2005 Mar;184(3):931-7. doi: 10.2214/ajr.184.3.01840931.
We sought to evaluate and compare the relative cost-benefit of Doppler sonography, MR angiography, and captopril-enhanced renal scintigraphy as techniques for predicting a patient's clinical response to renal angioplasty.
Estimations of positive and negative predictive values of baseline and captopril-enhanced renal scintigraphy and Doppler sonography examinations for predicting a favorable outcome after renal angioplasty were based on a previously published prospective study involving 74 patients who underwent this treatment. For gadolinium-enhanced MR angiography, predictive values were calculated from a subpopulation of 57 of these 74 subjects. The value of different combined strategies with these techniques for predicting clinical success after angioplasty was evaluated in this population. The costs of investigation and treatment per improved patient were calculated for each imaging technique and for combined strategies in a hypothetic 1,000-patient population with a 30% prevalence of renal artery stenosis, relying on the diagnostic performance reported in the literature for each technique in detecting renal artery stenosis.
The costs for each improved patient were $12,579 for patients selected on the basis of a positive finding on Doppler sonography (false-negative results = 12/1,000) and $10,149 for patients selected with criteria combining a positive finding on Doppler sonography with a bilateral resistive index of less than 0.75 (false-negative results = 32/1,000). Patient selection based on a positive finding on MR angiography cost $18,119 (false-negative results = 0), whereas the cost of patient selection based on a positive finding on renal scintigraphy was $12,939 (false-negative results = 29/1,000).
Doppler sonography is more cost-efficient but less sensitive than MR angiography for identifying patients with renovascular hypertension. MR angiography should be favored in hypertensive patients who are resistant to medical therapy to avoid false-negative examinations.
我们试图评估并比较多普勒超声、磁共振血管造影和卡托普利增强肾闪烁显像作为预测患者肾血管成形术临床反应的技术的相对成本效益。
基于一项先前发表的前瞻性研究,该研究纳入了74例行此治疗的患者,对基线及卡托普利增强肾闪烁显像和多普勒超声检查预测肾血管成形术后良好结局的阳性和阴性预测值进行了估计。对于钆增强磁共振血管造影,预测值是根据这74名受试者中的57名亚组计算得出的。在该人群中评估了这些技术的不同联合策略对预测血管成形术后临床成功的价值。假设在1000名肾动脉狭窄患病率为30%的患者人群中,根据文献报道的每种技术检测肾动脉狭窄的诊断性能,计算每种成像技术及联合策略每改善一名患者的检查和治疗成本。
基于多普勒超声阳性结果选择的患者,每改善一名患者的成本为12579美元(假阴性结果 = 12/1000),而基于多普勒超声阳性结果与双侧阻力指数小于0.75的标准联合选择的患者,成本为10149美元(假阴性结果 = 32/1000)。基于磁共振血管造影阳性结果选择患者的成本为18119美元(假阴性结果 = 0),而基于肾闪烁显像阳性结果选择患者的成本为12939美元(假阴性结果 = 29/1000)。
对于识别肾血管性高血压患者,多普勒超声成本效益更高,但敏感性低于磁共振血管造影。对于药物治疗耐药的高血压患者,应优先选择磁共振血管造影以避免假阴性检查。